Disclosure of shareholdings – Holta Invest AS

05. May 2023 | 1 min read

Moss, 5 May 2023
 
Holta Invest AS is in the process of simplifying its group structure whereby its ownership in Gentian Diagnostics ASA, previously owned indirectly through Holta Life Sciences AS (which is wholly owned by Holta Invest AS) and Holta Horisont AS (which is 85% owned by Holta Invest AS) now are owned directly by Holta Invest AS.
The above re-organization has been completed by each of Holta Horisont AS and Holta Life Sciences AS on 5 May 2023 having sold all its 13,800 shares and 1,214,702 shares, respectively, in Gentian Diagnostics ASA to Holta Invest AS. Following the transaction from Holta Horisont AS and Holta Life Sciences AS to Holta Invest AS, Holta Invest AS holds 1,228,502 shares in Gentian, corresponding to approximately 7.97 per cent of the total shares and votes (based on 15,422,350 number of outstanding shares).
 
This disclosure is made pursuant to Section 4-2 of the Norwegian Securities Trading Act.

You may also read


Feb 12, 2026 - Ole Sørlie

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..

Feb 11, 2026 - Ole Sørlie

Update on the development of the NT-proBNP assay

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations..

Feb 11, 2026 - Ole Sørlie

Gentian Diagnostics: Fourth quarter 2025 report

Moss, 11 February 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..